healthcare-thumbnail.png

Brain and CNS Tumors Market Research Report

Published: 2025 - January

Report Code: VMR-17544

Region: Global

Request Sample
Customization
Ask an Expert
Enquire Enquire Before Buying

Brain and CNS Tumors Market Analysis

The Brain and CNS Tumors Market encompasses the diagnosis, treatment, and management of tumors affecting the brain and central nervous system. These tumors, which can be primary or secondary in origin, include a broad spectrum of malignancies such as glioblastomas, astrocytomas, and metastatic brain tumors. The market integrates advancements in pharmacology, biologics, immunotherapy, and precision medicine, aiming to address the unmet needs of patients while reducing the systemic burden of treatments.

Disruptive Impact and Opportunities:

This market is undergoing significant disruption due to innovative therapies and technological breakthroughs, offering opportunities to address key challenges in treatment efficacy, patient safety, and accessibility. Emerging therapies promise new mechanisms of action, such as oncolytic virotherapy and targeted biologics, ensuring easy integration with existing treatment protocols. A focus on safe and minimally invasive delivery methods, such as localized drug delivery and immunotherapy, has revolutionized patient care. The market is big due to its growth potential, fueled by rising incidence rates and robust R&D pipelines.

Brain and CNS Tumors Market Segmentation - Emerging Drugs

  • Eflornithine + Lomustine

  • Ofranergene obadenovec (VB-111)

  • Regorafenib

  • Durvalumab (MEDI4736)

  • Tasadenoturev (DNX-2401)

  • ONC201

  • Selinexor (KPT-330)

  • Ad-RTS-hIL-12 + Veledimex

  • Everolimus (RAD001)

Brain and CNS Tumors Market Segmentation - Marketed Drugs 

  • Avastin

  • Temodar/Temodal

  • Lomustine (CCNU, Gleostine)

  • Procarbazine (Matulane)

  • Vincristine (Vincasar)

Key Companies:

  • Genentech
  • Merck
  • Orbus Therapeutics
  • VBL Therapeutics
  • Bayer
  • MedImmune
  • DNAtrix
  • Oncoceutics
  • Karyopharm Therapeutics
  • Ziopharm
  • Novartis

Brain and CNS Tumors Market Segmentation -  By Type

·  Primary Tumors

  • Gliomas

    • Astrocytomas

    • Oligodendrogliomas

    • Ependymomas

    • Glioblastomas

  • Meningiomas

  • Pituitary Tumors

  • Schwannomas

  • Craniopharyngiomas

  • Pineal Tumors

·  Secondary (Metastatic) Tumors

  • Lung Cancer Metastases

  • Breast Cancer Metastases

  • Melanoma Metastases

  • Other Metastases

·  Non-Malignant Tumors

  • Benign Brain Tumors

  • Benign Spinal Cord Tumors

Brain and CNS Tumors Market Segmentation -  By Administration Type

·  Oral

  • Tablets

  • Capsules

·  Parenteral

  • Intravenous (IV)

  • Intrathecal

·  Topical

  • Ointments

  • Patches

·  Other Administration Methods

  • Implantable Devices

  • Localized Drug Delivery Systems

What’s in It for You?

  • Detailed analysis of emerging therapies and their potential to disrupt the market.

  • Insights into competitive dynamics and strategic positioning of key players

  • Data-driven opportunities for investment in R&D pipelines.

  • Comprehensive forecasts to support strategic decision-making.

Brain and CNS Tumors Market Analysis (Market Size & CAGR, Epidemiology, Marketed Therapies, Emerging Drugs, Clinical Trials, Key Approvals & Anticipated Loss of Exclusivity, Opportunities, Unmet Needs, Company Profiles)

1. Brain and CNS Tumors Market - Executive Summary

               1.1         Introduction       

               1.2         Objectives          

               1.3         Key Findings       

                              1.3.1 Market Size 2025 & 2030: By Key Country (10MM) 

                              1.3.2 Global Market Size 2025 & 2030: By Key Segment   

                              1.3.3 Key Investments & Startup Analysis              

               1.4         Research Methodology  

2. Understanding the Disease

               2.1         Disease Overview            

               2.2         Classification      

               2.3         Signs and Symptoms       

               2.4         Risk Factors       

               2.5         Causes 

               2.6         Disease Biology & Digital Innovations      

               2.7         Stages & Staging System              

               2.8         Diagnostic Algorithm      

               2.9         Current Treatment Practices & Algorithm              

               2.10       Current Standard of Care and Treatment Gaps    

               2.11       Patient Demographics and Treatment Pathways  

3. Guidelines

4. Unmet Needs

5. Epidemiology and Patient Population                                     

               5.1         Epidemiology Key Findings           

               5.2         Assumptions and Rationale: 10MM         

               5.3         Epidemiology Scenario: 10MM   

               5.4         U.S. Epidemiology Scenario         

               5.5         EU-5 Epidemiology          

                              5.5.1 U.K. Epidemiology Scenario             

                              5.5.2 Germany Epidemiology Scenario    

                              5.5.3 France Epidemiology Scenario         

                              5.5.4 Italy Epidemiology Scenario             

                              5.5.5 Spain Epidemiology Scenario           

               5.6         Japan Epidemiology Scenario      

               5.7         China Epidemiology Scenario      

               5.8         Australia Epidemiology Scenario

               5.9         India Epidemiology Scenario       

6. Real-world Data & Real-world Evidence                                

7. Drug Development Landscape                                  

               7.1         Existing Key Drug Candidate Profiles/ Marketed Therapies             

                              7.1.1 Avastin     

                                             7.1.1.1 Product Description

                                             7.1.1.2 Regulatory Milestones

                                             7.1.1.3 Other Developmental Activities

                                             7.1.1.4 Pivotal Clinical Trials

                                             7.1.1.5 Ongoing Current Pipeline Activity

                              7.1.2 Temodar/Temodal 

                              7.1.3 Procarbazine (Matulane)    

                              7.1.4 Vincristine (Vincasar)          

               7.2         Competitive Analysis and Differentiation

               7.3         Overview of Similar/Competing Drugs in Clinical Trials     

               7.4         Future Trends and Emerging Drugs          

                              7.4.1 Eflornithine + Lomustine    

                              7.4.2 Durvalumab (MEDI4736)   

                              7.4.3 Tasadenoturev (DNX-2401)              

                              7.4.4 Selinexor (KPT-330)              

8. Regulatory Strategy and Potential Challenges                                    

               8.1         Regulatory Pathways in Key Markets       

               8.2         Anticipated Regulatory Hurdles and Mitigation Strategies              

               8.3         Case Studies in Oncology Drug Regulation             

               8.4         Impact of Potential Changes to Regulatory Framework    

9. Commercial Landscape                                

               9.1         Market Size & Growth Rates       

               9.2         Key Approvals & Anticipated Loss of Exclusivity   

               9.3         PESTLE & Porter’s Five Forces Analysis    

               9.4         Market Shares, Positioning/Ranking         

               9.5         Market Drivers  

               9.6         Identification of Threats

               9.7         Digital Evolution in Commercialization     

10. Market Segmentation                                   

               10.1       Market by Therapy Type

                              10.1.1 Targeted Therapy

                              10.1.2 Chemotherapy     

                              10.1.3 Immunotherapy  

                              10.1.4 Others    

11. Pricing, Reimbursement, and Access                                     

               11.1       Competitive Pricing Analysis       

               11.2       Reimbursement Landscape and Challenges          

               11.3       Strategies for Market Access and Equity 

               11.4       Patient Spending/Expenditure Analysis   

12. Future Trends, Disruptions, and Opportunities                                   

               12.1       Analysis of Emerging Trends        

               12.2       Technological Impact     

               12.3       Impact of Potential Market Disruptors     

               12.4       Opportunities for Future Development and Expansion     

               12.5       Considerations for Investment Opportunities       

13. Global Market Dynamics                                            

               13.1       Regional Regulatory Disparities  

               13.2       Cross-Border Partnership Strategies         

               13.3       Global Supply Chain Dynamics    

               13.4       Case Studies: Success and Failure in Global Markets         

               13.5       Strategies for Global Expansion and Localization 

14. Company Profiles                                          

               14.1       Y-mAbs Therapeutics Inc.            

               14.2       Shimadzu Corporation    

               14.3       Bristol-Myers Squibb      

               14.4       Bayer AG            

               14.5       AstraZeneca plc

               14.6       Johnson & Johnson Inc.

               14.7       Merck & Co.      

               14.8       Pfizer Inc.           

               14.9       F. Hoffmann-La Roche Ltd            

               14.10     Dr. Reddy's Laboratories Ltd        

Download Sample

↻

The field with (*) is required.

Choose License Type

$

2500

$

4250

$

5250

$

6900

Request Sample
Customization
Ask an Expert
Enquire Before Buying
customer-support

Analyst Support

Every order comes with Analyst Support.

report-custom

Customization

We offer customization to cater your needs to fullest.

verify

Verified Analysis

We value integrity, quality and authenticity the most.

© 2025 Virtue Market Research. All Rights Reserved.